FactSet Research Systems Inc. (NYSE: FDS), a leading provider of data analytics services, announced financial results for the second quarter of 2024, reporting higher revenues and adjusted profit.
- Q2 revenues increased 6% to $545.9 million from $515.1 million in the prior year period. Organic revenues grew 6.0%
- Annual subscription value, plus professional services, was $2.21 billion at the end of the quarter, vs. $2.1 billion last year
- Operating margin increased to 33.3% in the second quarter from 32.9% for the same period of 2023
- Net income, on a per-share basis, increased 8% to $3.65 in the February quarter from $3.38 a year earlier, due to higher revenues and margin expansion
- Adjusted earnings per share moved up 11.1% to $4.22 in Q2 from $3.80 in the comparable period last year
- Second-quarter adjusted EBITDA was $218.1 million, up 9.2% from $199.7 million reported in Q2 2023
- The management expects organic ASV, plus professional services, to grow in the range of $110 million to $150 million
- Full-year revenues are expected to be in the range of $2.20 billion to $2.21 billion
- The company is looking for earnings in the range of $13.95 per share to $14.35 per share for 2024
- Adjusted earnings per share is expected to be between $15.60 and $16.00 in the fiscal year
Listen to the conference calls as they happen. Don't miss a beat! With AlphaStreet Intelligence, you can listen to live calls and interviews as they happen, so you never have to worry about missing out on important information.
Most Popular
Citigroup set to report Q4 2025 earnings. Here’s what to expect
Citigroup Inc. (NYSE: C) has undergone a sweeping transformation in recent years, emerging as a more streamlined and profitable financial institution. The bank's performance in recent quarters has underscored the
Home Depot (HD), Lowe’s (LOW): Home improvement pressures not expected to abate soon
Home improvement retailers Home Depot (NYSE: HD) and Lowe’s Companies, Inc. (NYSE: LOW) have been facing a challenging operating environment for a while now. The companies have been battling macroeconomic
Earnings Summary: AngioDynamics (ANGO) Q2 FY26 sales increase 8.8%
Medical technology company AngioDynamics, Inc. (NASDAQ: ANGO) on Tuesday reported an increase in net sales for the second quarter of fiscal 2026. In Q2, net sales increased 8.8% year-over-year to
